NASDAQ · BEAM
Beam Therapeutics Inc.
Healthcare · Biotechnology
$24.52▲ 1.20% ($0.29)at close
After hours$24.55▲ 0.12%7:30 PM ET
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
9 of 10 projected years produce negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
Data notes
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
- 10-yr revenue CAGR
- 11.5%
- Ending operating margin
- 0.0%
- Discount rate
- 17.4%
USD · TTM ending Jun 30, 2026 · Price used $24.52 · Price Sep 29, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock rose 2.55% over the last year. Revenue grew 158.88% over the trailing twelve months. Operating margin moved from -739.94% to -242.27%. Free cash flow declined 4.84% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -242.27%. A decisive move in revenue — currently up 158.88% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
18
Buy
8
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 3, 2026
Q3 FY26 · EPS est -$1.16 · Revenue est $8.75M
View
Institutional Sentiment
Beam Therapeutics Inc. · BEAM
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.